CJC-1295 DAC vs Follistatin-344.

CJC-1295 with DAC (also written DAC:GRF, CJC-1295 DAC) is a synthetic, long-acting analog of growth hormone-releasing hormone (GHRH). It is built on the bioactive N-terminal GHRH(1-29) fragment with several amino-acid substitutions, plus a "Drug Affinity Complex" (DAC): a maleimidopropionyl group that lets the peptide bind covalently to circulating albumin after injection. It was developed in the mid-2000s by ConjuChem Biotechnologies as an investigational drug; it is not an approved medicine and today circulates mainly as a research/gray-market peptide.

Follistatin-344 (FS-344) is an alternatively spliced isoform of human follistatin, a naturally occurring secreted glycoprotein that acts as a high-affinity antagonist of several TGF-beta superfamily ligands. The "344" refers to a 344-amino-acid precursor variant; relative to the longer FS-315 serum isoform, it lacks the C-terminal acidic tail and was selected for therapeutic use partly to reduce off-target heparin/cell-surface binding. In gene-therapy programs it is the FS344 transgene that is delivered, not an injected peptide product, although it is now marketed in gray-market channels as a "research peptide."

Like native GHRH, CJC-1295 binds the GHRH receptor on anterior pituitary somatotrophs and stimulates synthesis and pulsatile release of growth hormone (GH), which in turn drives hepatic and peripheral IGF-1 production. Two engineering features extend its action: amino-acid substitutions in the GHRH(1-29) backbone resist cleavage by dipeptidyl-peptidase-4 (DPP-4), and the DAC maleimide group forms a covalent bond with cysteine-34 of serum albumin, shielding the peptide from renal filtration and proteolysis so it persists in plasma for days rather than minutes. Because it amplifies the body's own GH axis rather than supplying exogenous GH, secretion remains somewhat pulsatile and subject to negative feedback (e.g., somatostatin).

Follistatin works by binding and neutralizing myostatin (GDF-8) and related ligands such as activin A, GDF-11, and several BMPs, preventing them from engaging activin type II receptors. Because myostatin is a dominant negative regulator of skeletal muscle mass, removing this brake promotes satellite-cell activation, myofiber hypertrophy, and reduced fibrosis. Critically, follistatin neutralizes a broader set of ligands than myostatin-only blockade, which is why follistatin overexpression produces larger muscle gains in animals than myostatin knockout alone. The foundational biology traces to McPherron, Lawler and Lee (Nature, 1997), who showed myostatin loss roughly doubles muscle mass in mice.

Human evidence comes mainly from early-phase ConjuChem trials in healthy adults. Teichman et al. (JCEM, 2006) reported that single subcutaneous doses produced dose-dependent, sustained elevations of GH and IGF-1, with IGF-1 remaining above baseline for several days and repeated weekly/biweekly dosing maintaining elevated IGF-1. Ionescu and Frohman (JCEM, 2006) showed that despite continuous GHRH-receptor stimulation, GH secretion remained pulsatile in healthy men. Preclinical support includes Alba et al. (Am J Physiol Endocrinol Metab, 2006), where once-daily CJC-1295 normalized growth in GHRH-knockout mice, and Sackmann-Sala et al. (Growth Horm IGF Res, 2009), which characterized GH/IGF-1-axis-driven serum protein changes. Crucially, there are no published controlled trials demonstrating clinical outcomes (body composition, strength, fat loss, anti-aging, or healing) in humans; the human data establish a pharmacodynamic GH/IGF-1 effect, not proven therapeutic benefit, and the program was discontinued without an approved indication.

Human evidence is limited to two small, open-label AAV1-delivered FS344 gene-therapy trials from Nationwide Children's Hospital (Mendell and colleagues), not to any injected-peptide product. A Phase 1/2a trial in Becker muscular dystrophy (6 subjects; Mol Ther 2015, PMID 25322757) reported six-minute-walk gains in some treated patients (e.g., +58 m and +125 m in two subjects) with histological evidence of reduced fibrosis and fiber hypertrophy. A companion sporadic inclusion body myositis trial (6 subjects; Mol Ther 2017, PMID 28279643) reported improved annualized six-minute-walk distance versus untreated controls, though responses were heterogeneous and the comparison used a non-randomized matched control group. These are early-phase, unblinded, very small studies; large-animal support comes from a nonhuman-primate follistatin gene-delivery study (Kota et al., Sci Transl Med 2009, PMID 20368179). No randomized controlled trial, and no trial of FS-344 as a standalone injectable peptide, has demonstrated efficacy. The sIBM functional claims also drew a published methodological critique in Molecular Therapy.

In the short early-phase human studies, the most consistently noted effects were injection-site reactions and transient flushing; sustained IGF-1 elevation also raises theoretical concerns common to GH-axis stimulation, such as fluid retention, joint discomfort, carpal-tunnel-type symptoms, and reduced insulin sensitivity. Long-term human safety is essentially uncharacterized: no large or long-duration controlled trials were completed, and chronically elevated GH/IGF-1 is a biologically plausible (though unproven for this compound) concern for promoting growth of existing neoplasms. Real-world risk is compounded by the fact that material sold as "CJC-1295 DAC" is unregulated and may vary in purity, identity, or sterility. No dosing or administration guidance is provided here.

In the two small gene-therapy trials, intramuscular AAV1.FS344 was reported as generally well tolerated over follow-up exceeding two years, but these cohorts are far too small to characterize real risk. Because follistatin broadly inhibits TGF-beta/activin signaling, theoretical and preclinical concerns include effects on reproductive tissues (follistatin was first identified as an inhibitor of FSH secretion), the pituitary-gonadal axis, vascular and cardiac remodeling, and possible influence on tumor biology, none of which are adequately resolved in humans. Gray-market "follistatin-344 peptide" products carry the additional, unquantified hazards of unverified identity, purity, sterility, and the fundamental mismatch that human data come from a delivered gene, not an injected protein. There is no established human safety profile for self-administered FS-344.

CJC-1295 (with or without DAC) is not approved by the FDA or any major regulator for any use; clinical development was discontinued and it is treated as an unapproved/investigational substance, with U.S. authorities also flagging it as unsuitable for pharmacy compounding. It is prohibited in sport at all times by the World Anti-Doping Agency as a GH-releasing factor under Category S2 of the Prohibited List.

Follistatin-344 is not approved by the FDA (or any major regulator) for any indication; it has only been studied investigationally as an AAV-delivered gene therapy and is sold elsewhere strictly as a research-use-only chemical, not a medicine. Myostatin-pathway inhibition is also of interest to anti-doping bodies, and follistatin/myostatin inhibitors fall under WADA's prohibited categories.